Loading
A phase 3 trial of Giredestrant in advanced solid tumours, run by Genentech, Inc., now recruiting.
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) is a phase 3 interventional study registered as NCT07541079 by Genentech, Inc., with 300 participants planned, started 2026-08-25 and due to reach its primary completion in 2032-06-30. Interventions recorded: Giredestrant.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.